162 results on '"Pollard, Richard B."'
Search Results
2. Summary of Panel Discussion about Antiviral Therapy for Zoster
3. Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy
4. Plasma-derived HIV Nef+ exosomes persist in ACTG384 study participants despite successful virological suppression
5. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202
6. Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation
7. Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy
8. Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
9. Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
10. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
11. Peginterferon α-2a for the treatment of HIV infection
12. Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case–Cohort Study
13. Immunotherapy of Viral Infections Other than HIV
14. Clinical and Correlative Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Previously Untreated Indolent Non-Hodgkin Lymphoma
15. Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164
16. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial
17. A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects
18. Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy
19. Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction
20. Refractory AIDS cholangiopathy
21. Impact of highly active antiretroviral therapy initiation on CD4+ T-cell repopulation in duodenal and rectal mucosa
22. HIV Disease Activity as a Modulator of Lipoprotein(a) and Allele-Specific Apolipoprotein(a) Levels
23. Short Communication: HIV+ Viremic Slow Progressors Maintain Low Regulatory T Cell Numbers in Rectal Mucosa but Exhibit High T Cell Activation
24. Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens
25. Generation of an HIV-1-Resistant Immune System with CD34 + Hematopoietic Stem Cells Transduced with a Triple-Combination Anti-HIV Lentiviral Vector
26. Host Gene Expression Changes Correlating With Anti–HIV-1 Effects in Human Subjects After Treatment With Peginterferon Alfa-2a
27. Mitochondrial Genomics and CD4 T-Cell Count Recovery After Antiretroviral Therapy Initiation in AIDS Clinical Trials Group Study 384
28. Increased Frequency of Regulatory T Cells Accompanies Increased Immune Activation in Rectal Mucosae of HIV-Positive Noncontrollers
29. Molecular Characterization of Stool Microbiota in HIV-Infected Subjects by Panbacterial and Order-Level 16S Ribosomal DNA (rDNA) Quantification and Correlations With Immune Activation
30. A Randomized Trial of Interleukin-2 During Withdrawal of Antiretroviral Treatment
31. HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4 + T-Cell Responses
32. Immunodominant HIV-Specific CD8 + T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers
33. Comparison of Immunologic Assays for Detecting Immune Responses in HIV Immunotherapeutic Studies: AIDS Clinical Trials Group Trial A5181
34. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
35. Pretreatment Levels of Soluble Cellular Receptors and Interleukin‐6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral Therapy
36. Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial
37. W1830 CD4+ T-Cell Depletion in Gut-Associated Lymphoid Tissue and CD8+ T-Cell Hyperactivation in Peripheral Blood are Linked to Greater Gut-Proportion of Enterobacteriales and Bacteroidales in HIV Therapy Pre-Clinical Trial Analysis
38. Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)
39. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
40. Proteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral‐Naive HIV‐Infected Subjects
41. Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1
42. Inhibitory effect of glycyrrhizin on the neutrophil‐dependent increase of R5 HIV replication in cultures of macrophages
43. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control
44. The effect of aging on T-regulatory cell frequency in HIV infection
45. Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naive Subjects
46. Magnitude and Complexity of Rectal Mucosa HIV-1-Specific CD8+ T-Cell Responses during Chronic Infection Reflect Clinical Status
47. A Cytomegalovirus Vaccine for Transplantation: Are We Closer?
48. Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy
49. Interleukin 2 and HIV RNA Levels—Reply
50. Multifunctional Human Immunodeficiency Virus (HIV) Gag-Specific CD8 + T-Cell Responses in Rectal Mucosa and Peripheral Blood Mononuclear Cells during Chronic HIV Type 1 Infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.